Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.
Strathcona Resources Ltd. (TSE:SCR – Get Free Report) hit a new 52-week low during trading on Wednesday . The company traded as low as C$20.91 and last traded at C$20.99, with a volume of 105126 shares traded. The stock had previously closed at C$21.89. Analysts Set New Price Targets A number of equities research analysts […]